<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01238848</url>
  </required_header>
  <id_info>
    <org_study_id>HGNPE-14-2010</org_study_id>
    <nct_id>NCT01238848</nct_id>
  </id_info>
  <brief_title>Efficacy of Nebulized Hypertonic Saline in the Treatment of Acute Bronchiolitis</brief_title>
  <acronym>Hypertonic</acronym>
  <official_title>A Randomized Controlled Trial to Evaluate Efficacy of Nebulized Hypertonic Saline vs. Normal Saline in the Treatment of Hospitalized Children With Bronchiolitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General de Niños Pedro de Elizalde</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital General de Niños Pedro de Elizalde</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of hypertonic saline vs. normal saline
      in the treatment of infants hospitalized for bronchiolitis, regarding length of hospital
      stay, oxygen requirements and clinical outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite bronchiolitis is a very frequent disease among infants, there are still controversies
      regarding its treatment. Hypertonic saline has been proposed as useful treatment in these
      children, bur information is still controversial.

      The aim is to asses that using Nebulized Hypertonic Saline with bronchodilators (albuterol)
      may reduce the days of hospitalization and improve clinical outcomes in patients with acute
      bronchiolitis, compared with using Normal Saline with albuterol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospitalization Days</measure>
    <time_frame>Participants will be followed for the duration of hospitalization, an expected average of 4 days</time_frame>
    <description>hospitalization days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of Oxygen Use</measure>
    <time_frame>Participants will be followed for the duration of hospitalization, an expected average of 4 days</time_frame>
    <description>Length of oxygen use (days)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Bronchiolitis</condition>
  <arm_group>
    <arm_group_label>Hypertonic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nebulized hypertonic saline (sodium chloride 3%) + albuterol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Normal saline (sodium chloride 0.9%) + albuterol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypertonic saline</intervention_name>
    <description>3 cc nebulized hypertonic saline + albuterol 0.25 mg/kg/day, four times a day (QID), 5 days</description>
    <arm_group_label>Hypertonic</arm_group_label>
    <other_name>ClNa 3% (sodium chloride 3%)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>3 cc nebulized normal saline + albuterol 0.25 mg/kg/day, four times a day (QID), 5 days</description>
    <arm_group_label>Normal</arm_group_label>
    <other_name>ClNa 0.9% (sodium chloride 0.9%)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Infants aged 1 to 24 months, hospitalized for first episode of bronchiolitis, with
             severity score ≥ 5 points and oxygen saturation ≥ 97%.

        Exclusion Criteria:

          -  Chronic respiratory or cardiovascular disease, respiratory failure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>2 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria I Espelt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General de Niños Pedro de Elizalde</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital General de Niños Pedro de Elizalde</name>
      <address>
        <city>Buenos Aires</city>
        <state>CF</state>
        <zip>C1270AAN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <reference>
    <citation>Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP. Nebulized hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database Syst Rev. 2008 Oct 8;(4):CD006458. doi: 10.1002/14651858.CD006458.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;7:CD006458.</citation>
    <PMID>18843717</PMID>
  </reference>
  <reference>
    <citation>Ralston S, Hill V, Martinez M. Nebulized hypertonic saline without adjunctive bronchodilators for children with bronchiolitis. Pediatrics. 2010 Sep;126(3):e520-5. doi: 10.1542/peds.2009-3105. Epub 2010 Aug 16.</citation>
    <PMID>20713480</PMID>
  </reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2010</study_first_submitted>
  <study_first_submitted_qc>November 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2010</study_first_posted>
  <results_first_submitted>July 16, 2012</results_first_submitted>
  <results_first_submitted_qc>July 16, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 17, 2012</results_first_posted>
  <last_update_submitted>December 20, 2016</last_update_submitted>
  <last_update_submitted_qc>December 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertonic</keyword>
  <keyword>Saline</keyword>
  <keyword>Bronchiolitis</keyword>
  <keyword>Efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiolitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hypertonic</title>
          <description>Hypertonic saline (sodium chloride 0.3%) + albuterol</description>
        </group>
        <group group_id="P2">
          <title>Normal</title>
          <description>Normal saline (sodium chloride 0.9%) + albuterol</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hypertonic</title>
          <description>Hypertonic saline (sodium chloride 0.3%) + albuterol</description>
        </group>
        <group group_id="B2">
          <title>Normal</title>
          <description>Normal saline (sodium chloride 0.9%) + albuterol</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.6" spread="4.1"/>
                    <measurement group_id="B2" value="4.2" spread="2.5"/>
                    <measurement group_id="B3" value="4.5" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Length of Oxygen Use</title>
        <description>Length of oxygen use (days)</description>
        <time_frame>Participants will be followed for the duration of hospitalization, an expected average of 4 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hypertonic</title>
            <description>Hypertonic saline (sodium chloride 0.3%) + albuterol</description>
          </group>
          <group group_id="O2">
            <title>Normal</title>
            <description>Normal saline (sodium chloride 0.9%) + albuterol</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Oxygen Use</title>
          <description>Length of oxygen use (days)</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="3.4"/>
                    <measurement group_id="O2" value="3.22" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hospitalization Days</title>
        <description>hospitalization days</description>
        <time_frame>Participants will be followed for the duration of hospitalization, an expected average of 4 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hypertonic</title>
            <description>Hypertonic saline (sodium chloride 0.3%) + albuterol</description>
          </group>
          <group group_id="O2">
            <title>Normal</title>
            <description>Normal saline (sodium chloride 0.9%) + albuterol</description>
          </group>
        </group_list>
        <measure>
          <title>Hospitalization Days</title>
          <description>hospitalization days</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="2.7"/>
                    <measurement group_id="O2" value="5.47" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Hypertonic</title>
          <description>Hypertonic saline (sodium chloride 0.3%) + albuterol</description>
        </group>
        <group group_id="E2">
          <title>Normal</title>
          <description>Normal saline (sodium chloride 0.9%) + albuterol</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The initially estimated sample size was not achieved</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Maria I. Espelt, MD</name_or_title>
      <organization>Hospital General de Niños Pedro de Elizalde</organization>
      <phone>541146136968</phone>
      <email>cespelt@fibertel.com.ar</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

